GALNT12与C1GALT1交互作用与半乳糖缺陷型IgA1及IgA肾病相关
该研究对1127例IgA肾病患者进行血清半乳糖缺陷型IgA1水平的全基因组关联研究,发现C1GALT1和GALNT12两个位点达全基因组显著性,分别解释约3.7%和3.4%的变异,并证实GALNT12与C1GALT1在半乳糖缺陷型IgA1水平和疾病风险上存在遗传交互作用。
要点
- GALNT12是新发现的与血清半乳糖缺陷型IgA1水平相关的基因。
- GALNT12与C1GALT1存在遗传交互作用,影响半乳糖缺陷型IgA1水平和IgA肾病风险。
- IgA肾病患者GALNT12 mRNA表达显著低于健康对照。
核心结论
- GALNT12是与半乳糖缺陷型IgA1相关的新基因,并提示其与C1GALT1存在遗传交互作用。
- 研究结果支持遗传决定的半乳糖缺陷型IgA1调控异常在IgA肾病发病中起关键作用。
研究设计与样本
- 基于两个全基因组关联研究面板,对1127例IgA肾病患者进行血清半乳糖缺陷型IgA1水平的定量全基因组关联研究。
- 纳入2352例经活检诊断的IgA肾病患者和2632例健康对照进行遗传关联分析。
- 收集59例患者和27例健康对照的外周血样本进行基因表达分析。
主要发现
- 发现C1GALT1和GALNT12两个位点达全基因组显著性,分别解释血清半乳糖缺陷型IgA1水平约3.7%和3.4%的变异。
- 证实C1GALT1与血清半乳糖缺陷型IgA1水平的关联,领先SNP为rs10238682(β=0.26,P=1.20×10-9)。
- 新发现GALNT12位点rs7856182与血清半乳糖缺陷型IgA1水平相关(β=0.73,P=2.38×10-9)。
- GALNT12与C1GALT1在半乳糖缺陷型IgA1水平(P=1.40×10-2)和疾病风险(P=6.55×10-3)上存在遗传交互作用。
- IgA肾病患者GALNT12 mRNA表达显著低于健康对照。
临床怎么用
- GALNT12和C1GALT1的遗传变异可能有助于识别半乳糖缺陷型IgA1水平升高及IgA肾病易感人群。
- GALNT12 mRNA表达降低与IgA肾病相关,提示其可能作为潜在的生物标志物或治疗靶点进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Galactose-deficient IgA1 plays a key role in the pathogenesis of IgA nephropathy, the most common primary GN worldwide. Although serum levels of galactose-deficient IgA1 have a strong genetic component, the genetic link between this molecule and IgA nephropathy has not yet been clearly established. METHODS: To identify novel loci associated with galactose-deficient IgA1, we performed a quantitative genome-wide association study for serum galactose-deficient IgA1 levels, on the basis of two different genome-wide association study panels conducted in 1127 patients with IgA nephropathy. To test genetic associations with susceptibility to IgA nephropathy, we also enrolled 2352 patients with biopsy-diagnosed IgA nephropathy and 2632 healthy controls. Peripheral blood samples from 59 patients and 27 healthy controls were also collected for gene expression analysis. RESULTS: We discovered two loci, in C1GALT1 and GALNT12, that achieved genome-wide significance, explaining about 3.7% and 3.4% of variance in serum galactose-deficient IgA1 levels, respectively. We confirmed the previously reported association of C1GALT1 with serum galactose-deficient IgA1 levels, but with a different lead single-nucleotide polymorphism (rs10238682; β=0.26, P=1.20×10-9); the locus we identified at GALNT12 (rs7856182; β=0.73, P=2.38×10-9) was novel. Of more interest, we found that GALNT12 exhibits genetic interactions with C1GALT1 in both galactose-deficient IgA1 levels (P=1.40×10-2) and disease risk (P=6.55×10-3). GALNT12 mRNA expression in patients with IgA nephropathy was significantly lower compared with healthy controls. CONCLUSIONS: Our data identify GALNT12 as a novel gene associated with galactose-deficient IgA1 and suggest novel genetic interactions. These findings support a key role of genetically conferred dysregulation of galactose-deficient IgA1 in the development of IgA nephropathy.
引用
- Wang YN, Zhou XJ, Chen P, et al. Interaction between GALNT12 and C1GALT1 Associates with Galactose-Deficient IgA1 and IgA Nephropathy. J Am Soc Nephrol. 2021. PMID: 33593824. doi:10.1681/ASN.2020060823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。